This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LHC Group Finalizes Joint Venture Agreement With AtlantiCare
by Zacks Equity Research
LHC Group's (LHCG) deal is in line with its current strategy of collaborating with JV partners to expand service capabilities in core markets.
Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges
by Zacks Equity Research
We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.
Here's Why You Should Invest in Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.
Myriad Genetics' (MYGN) POLO Study Shows Positive Results
by Zacks Equity Research
Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.
Luminex xMAP Picked by EDP Biotech to Boost Cancer Diagnostics
by Zacks Equity Research
Management at Luminex (LMNX) expects to see robust demand for Luminex's xMAP technology in 2019.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
by Zacks Equity Research
Bio-Rad (BIO) continues to witness high investor confidence on strength in the Life Sciences segment.
Has Penumbra (PEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PEN) Outperforming Other Medical Stocks This Year?
Medtronic Receives FDA Nod for SelectSite Catheter System
by Zacks Equity Research
The launch of the SelectSite catheter is in line with Medtronic's (MDT) goal to expand its cardiac care portfolio.
Masimo's Technologies to be Deployed to Boost Pediatric Care
by Zacks Equity Research
NuVision's centers are to be equipped with Masimo's (MASI) SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet technologies.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX (IDXX) registers strong revenue growth on the back of CAG Diagnostics.
QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients
by Zacks Equity Research
QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.
Here's Why You Should Retain NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investor confidence in the stock is high on NuVasive's (NUVA) sturdy spine business.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Investor confidence in the stock is high on Hill-Rom's (HRC) recent acquisition of Voalte.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian Medical (VAR) raises revenue guidance for 2019 encourages.
AngioDynamics IDE Application for NanoKnife Gets FDA Nod
by Zacks Equity Research
AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) benefits from launches like Halo ION.
Penumbra, Olympic Steel, Facebook, Alphabet and Netflix highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Penumbra, Olympic Steel, Facebook, Alphabet and Netflix highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $4 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Penumbra (PEN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 76.92% and 5.30%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical (ISRG) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
Intuitive Surgical's (ISRG) Q1 results outside the United States impress.
Edwards Lifesciences Takes Over CAS Medical Systems for $100M
by Zacks Equity Research
This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed (CHE) is expected to benefit from the launch of its VITAS Healthcare Inpatient Hospice Unit.
Medidata Launches Acorn Artificial Intelligence Company
by Zacks Equity Research
Driven by Medidata's (MDSO) standardized clinical data storehouse, and operating on its pioneering platform, Acorn AI is set to become one of the premier AI companies in the field of life sciences.
Stryker's LIFEPAK CR2 Defibrillator Launch to Boost MedSurg
by Zacks Equity Research
Stryker's (SYK) emergency care department offers a broad range of products and systems.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) has been benefitting from developments like the FDA clearance of the Rad-67 Pulse CO-Oximeter.